A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma - 25/07/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Efficacy and safety of combination iodine [131I] metuximab infusion and transcathether arterial chemoembolization (TACE) with those of TACE-alone for hepatocellular carcinoma (HCC) were compared. |
• | Literature search regarding controlled clinical trials comparing combination TACE and iodine [131I] metuximab infusion with TACE-alone for HCC treatment was done. |
• | This evidence-based medical analysis showed that treating unresectable liver cancer with combined 131I metuximab arterial infusion and TACE was safe and could increase 6-month survival, 1-year overall survival, and the response rate, relative to TACE alone. |
Summary |
Objectives |
To compare the efficacy and safety of combination iodine [131I] metuximab infusion and transcathether arterial chemoembolization (TACE) with those of TACE-alone for hepatocellular carcinoma (HCC).
Materials and methods |
PubMed, Cochrane Library, Embase, Web of Science, China Biology Medicine, China Science and Technology Journal Database, Wan Fang Data, and Chinese knowledge resource integrated databases were used for the literature search regarding controlled clinical trials comparing combination TACE and iodine [131I] metuximab infusion with TACE-alone for HCC treatment before February 1, 2016. The Jadad system evaluation method for research quality and RevMan 5.0 software were used for the meta-analysis.
Results |
In total, 1302 patients from 10 studies were included. The meta-analysis showed that the combination TACE and iodine [131I] metuximab infusion treatment for HCC was more effective than TACE alone, including 6-month survival (odds ratio [OR] = 2.05, 95% confidence interval [CI]: 1.41–2.98, P = 0.0002), 1-year survival (OR = 1.90, 95% CI: 1.41–2.55, P < 0.00001), and the total response rate (OR = 2.91, 95% CI: 2.08–4.07, P < 0.00001). Nine studies reported adverse reactions, mainly comprising poor appetite, nausea, vomiting, and abdominal discomfort. Fever, chills, and bone marrow suppression were more common in the combined treatment group, but abnormal liver function was not different between the two treatment groups. There was no report on serious complications or death directly related to either treatment.
Conclusions |
Compared with TACE alone, the combination of TACE with iodine [131I] metuximab infusion for treating unresectable HCC may improve local efficacy and overall survival in these types of patients.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatocellular carcinoma, TACE, Iodine [131I] metuximab infusion, Meta-analysis
Plan
Vol 43 - N° 4
P. 451-459 - août 2019 Retour au numéro
Article précédent
- Correlation between the DEPDC5 rs1012068 polymorphism and the risk of HBV-related hepatocellular carcinoma
- Wenxuan Liu, Ning Ma, Dongqiang Zhao, Xia Gao, Xiaolin Zhang, Lei Yang, Dianwu Liu
- Repeat surgery in HNF1alpha-inactivated adenomatosis
- Charles Balabaud, Christophe Laurent, Nora Frulio, Saint Paul Marie Christine, Brigitte Le Bail, Laurent Possenti, Jean Frédéric Blanc, Laurence Chiche, Paulette Bioulac-Sage
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?